Compare DexCom, Inc. (DXCM) vs Okta, Inc. (OKTA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Okta, Inc. — how do they compare? DexCom, Inc. trades at $84.11 (market cap $31.86B), while Okta, Inc. trades at $232.13 (market cap $38.50B). The key difference: Okta, Inc. is the larger of the two by market cap, and Okta, Inc. is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Okta, Inc. for 44 Days on average.
| DXCM | OKTA | |
|---|---|---|
Market Cap | $31.86B | $38.50B |
Volume | 3,607,070 | 2,479,621 |
Sector | Health | Technology |
52-Week High | $92.34 | $220.21 |
52-Week Low | $54.84 | $62.93 |
Typical Hold Time | 62 Days | 44 Days |
Enterprise Value | $31.32B | $36.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.41, showing modest daily gains of 0.13%. The stock demonstrates strong fundamental performance with consistent earnings beats and robust revenue growth, reaching $4.66 billion in 2025. Technical indicators show a bearish short-term trend with key support at $82. The company maintains impressive profitability with 20.12% net margins and 38.49% ROE, supported by growing adoption of CGM technology in diabetes care.
DXCM presents a compelling growth story with expanding market opportunities in Type 2 diabetes care. Analyst consensus remains strongly bullish with 81% buy ratings and $95.07 price target, suggesting 13% upside. Key risks include reimbursement challenges and competitive pressures. The company's strong cash flow generation and institutional support provide solid foundation for continued growth.
OKTA trades at $220.21, up 1.01% on the day, with a bullish technical signal from moving averages and strong analyst support (73.58% buy ratings). The company reported a net income of $28 million in 2025, marking a return to profitability after losses in prior years, with revenue growing to $2.61 billion. Recent news highlights its AI agent security initiatives, including the Blueprint Alliance unveiled at Oktane 2026.
The outlook is positive due to earnings beats, AI-driven growth potential, and improving cash flow, but risks include high valuation multiples (P/E of 132.66) and competitive pressures in cybersecurity. The stock trades above the consensus price target of $201.30, suggesting near-term consolidation may occur despite long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Okta, Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Read more on OKTA →
